Ratings by Nomura/Instinet (Christopher Marai)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/29/2020 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2020 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2020 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2020 | BeyondSpring Inc. | BYSI | Maintain | Buy (N/A) |
|
Details | ||
| 4/14/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 4/3/2020 | Stealth BioTherapeutics | MITO | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2020 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 3/12/2020 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 3/5/2020 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2020 | CytomX Therapeutics | CTMX | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2020 | Galapagos NV | GLPG | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2020 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2020 | Avrobio Inc. | AVRO | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2020 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2020 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2020 | Immunovant | IMVT | New Coverage | Buy (N/A) |
15.97 (44.96) |
181.53% | Details | |
| 2/3/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Buy (N/A) |
|
Details | ||
| 1/22/2020 | Deciphera | DCPH | Maintain | Buy (N/A) |
|
Details | ||
| 1/10/2020 | BeyondSpring Inc. | BYSI | New Coverage | Buy (N/A) |
15.49 (0.72) |
-95.35% | Details | |
| 1/10/2020 | Kadmon Holdings | KDMN | New Coverage | Buy (N/A) |
4.57 (9.50) |
107.88% | Details | |
| 12/23/2019 | Stealth BioTherapeutics | MITO | Maintain | Buy (N/A) |
|
Details | ||
| 12/18/2019 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2019 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 11/27/2019 | Redhill Biopharma | RDHL | Maintain | Buy (N/A) |
|
Details | ||
| 11/26/2019 | Global Blood Therapeutics | GBT | Maintain | Buy (N/A) |
|
Details | ||
| 11/22/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 11/13/2019 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 11/12/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2019 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2019 | Galapagos NV | GLPG | Maintain | Buy (N/A) |
|
Details | ||
| 11/4/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2019 | Avrobio Inc. | AVRO | New Coverage | Buy (N/A) |
14.40 (1.40) |
-90.28% | Details | |
| 10/24/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/22/2019 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2019 | Stealth BioTherapeutics | MITO | Maintain | Buy (N/A) |
|
Details | ||
| 10/16/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2019 | Stealth BioTherapeutics | MITO | Maintain | Buy (N/A) |
|
Details | ||
| 10/9/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 10/8/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 10/7/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 9/13/2019 | Denali Therapeutics Inc. | DNLI | New Coverage | Buy (N/A) |
19.05 (25.69) |
34.86% | Details | |
| 8/23/2019 | Retrophin | RTRX | Maintain | Buy (N/A) |
|
Details | ||
| 8/22/2019 | Retrophin | RTRX | Maintain | Buy (N/A) |
|
Details | ||
| 8/22/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/20/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2019 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 7/29/2019 | Galapagos NV | GLPG | Maintain | Buy (N/A) |
|
Details | ||
| 7/11/2019 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2019 | Protagonist Therapeutics | PTGX | Maintain | Buy (N/A) |
|
Details | ||
| 6/27/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 6/20/2019 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 6/19/2019 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2019 | CytomX Therapeutics | CTMX | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2019 | Stealth BioTherapeutics | MITO | Maintain | Buy (Buy) |
|
Details | ||
| 4/16/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Buy (N/A) |
|
Details | ||
| 4/15/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 4/12/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 3/21/2019 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2019 | Xencor, Inc. | XNCR | Maintain | Reduce (N/A) |
|
Details | ||
| 3/12/2019 | Stealth BioTherapeutics | MITO | New Coverage | Buy (N/A) |
16.81 (0.32) |
-98.1% | Details | |
| 3/8/2019 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/8/2019 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2019 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2019 | Xencor, Inc. | XNCR | Downgrade | Reduce (Neutral) |
33.72 (27.52) |
-18.39% | Details | |
| 2/12/2019 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 2/8/2019 | Solid Biosciences | SLDB | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2019 | MacroGenics | MGNX | Maintain | Buy (N/A) |
|
Details | ||
| 2/1/2019 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 2/1/2019 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 1/29/2019 | Galapagos NV | GLPG | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2019 | Galapagos NV | GLPG | Maintain | Buy (Buy) |
|
Details | ||
| 12/24/2018 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 12/24/2018 | Solid Biosciences | SLDB | Maintain | Buy (Buy) |
|
Details | ||
| 12/21/2018 | Sarepta Therapeutics | SRPT | Maintain | Buy (Buy) |
|
Details | ||
| 12/17/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (Reduce) |
|
Details | ||
| 12/11/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 12/6/2018 | Protagonist Therapeutics | PTGX | New Coverage | Buy (N/A) |
6.37 (154.94) |
2332.34% | Details | |
| 11/21/2018 | Marker Therapeutics | MRKR | New Coverage | Buy (N/A) |
6.63 (1.29) |
-80.54% | Details | |
| 11/19/2018 | Retrophin | RTRX | New Coverage | Buy (N/A) |
24.78 (24.25) |
-2.14% | Details | |
| 11/8/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 10/30/2018 | Galapagos NV | GLPG | Maintain | Buy (N/A) |
|
Details | ||
| 10/19/2018 | Incyte | INCY | Maintain | Buy (Buy) |
|
Details | ||
| 10/18/2018 | Global Blood Therapeutics | GBT | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 10/11/2018 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2018 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2018 | Advanced Drainage Systems | WMS | Maintain | Buy (Reduce) |
|
Details | ||
| 9/21/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 9/20/2018 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 9/11/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 8/13/2018 | Alnylam Pharmaceuticals | ALNY | Maintain | Reduce (N/A) |
|
Details | ||
| 5/7/0020 | Deciphera | DCPH | Downgrade | Neutral (Buy) |
57.15 (25.59) |
-55.22% | Details |
